A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia

Amy S Chappell, Geoffrey Owen Littlejohn, Daniel K Kajdasz, Morton Scheinberg, Deborah D'Souza, Harvey Moldofsky

Research output: Contribution to journalArticleResearchpeer-review

48 Citations (Scopus)


Objectives: Evaluate the efficacy and safety of duloxetine at doses up to 120mg once daily in patients with fibromyalgia. Methods: This was a phase 3, 60-week study, which included an 8-week open-label period followed by a 52-week, randomized, double-blind period. Patients received duloxetine 30mg daily for 1 week and duloxetine 60mg daily for 7 weeks and were then randomized to receive either 60 or 120mg daily (1:2 ratio).
Original languageEnglish
Pages (from-to)365 - 375
Number of pages11
JournalThe Clinical Journal of Pain
Issue number5
Publication statusPublished - 2009

Cite this